Narcolepsy Market, By Type (Type 1 and Type 2 Narcolepsy), By Treatment (Antidepressants, Stimulants, Sodium oxybate and Others), By Diagnosis (Poysomnogram, Multiple sleep latency test and Others), By End Users (Hospitals, Retail Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Narcolepsy is a medical disease characterized by excessive daily sleepiness and unexpected sleep bouts. A sudden loss of muscular tone (cataplexy) can occur as a result of this chronic sleep condition, resulting in weakness and loss of muscle control. Among the most prevalent symptoms of the disorder include sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep, and insomnia, among others. Around 70% of people suffer from cataplexy, a sudden loss of muscle strength that has been shown to have a significant impact on patients' emotional well-being. When going asleep or waking up, there may be inability to move or vivid hallucinations. Persons with narcolepsy sleep about the same number of hours per day as people without it, but their sleep is of lower quality. Because narcolepsy is a rare and underdiagnosed chronic disorder, many people go undetected around the world. The Narcolepsy Market accounted for US$ 1.797 billion in 2020 and is estimated to be US$ 4.205 billion by 2030 and is anticipated to register a CAGR of 8.9%.

Impact of Covid-19 pandemic on market

The neurobiology of sleep has advanced significantly in recent decades, owing to the improved availability of animal models that allow researchers to better understand the complexity of the brain, particularly the functional relationship between the brain and sleep. The novel coronavirus is causing severe respiratory distress, and severe respiratory failure has been a leading cause of death in many of the cases described thus far.

Rising initiatives by government bodies

Several local, national, and international institutes, organizations, and councils are working to raise knowledge of narcolepsy problems and the therapies that are available. For example, "Wake Up Narcolepsy" is a non-profit organization dedicated to raising awareness and directing the quest for a cure for disorders in order to promote community well-being. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a programmed called "Rising Voices of Narcolepsy" to train people with narcolepsy to share their stories through writing and verbally addressing local communities in order to raise awareness and reduce social stigma among others suffering from the disease. Patients' increased awareness and non-profit organizations’ actions are likely to increase patient awareness of narcolepsy treatments.

Rise in the severity of the disease

The rise in the severity of the disease and the number of persons affected by narcolepsy are the main factors driving the market for narcolepsy medications to grow. Narcolepsy medications can also be used to treat sleep apnea. Furthermore, the availability of a payment method for FDA-approved prescription pharmaceuticals increases demand. Furthermore, rising disposable income and increased knowledge of the benefits of narcolepsy medications are expected to drive global market expansion. The primary drivers of narcolepsy market growth throughout the predicted period are rising narcolepsy prevalence and a growing obese population. In addition, because it has less adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. As a result, proper treatment can aid in the prevention of such ailments, propelling the narcolepsy market forward over the projection period.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

The global Narcolepsy market is segmented based on type, treatment, diagnosis, and region.

On the basis of Type, the global Narcolepsy market is segmented into Type 1 and Type 2. Based on Treatment, the global Narcolepsy market is segmented into Antidepressants, Stimulants, sodium oxybate and Others. Based on Diagnosis, the target market is segmented into Poysomnogram, Multiple sleep latency test and Others.

Regional Insights:

On region the global Narcolepsy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. America dominates the global narcolepsy market. This is mainly attributed due to its well-developed healthcare industry, high healthcare spending, and large patient population. Furthermore, the presence of established economies like as the United States and Canada, as well as global businesses such as Mylan N.V., Ligand Pharmaceuticals, Inc., and others within the Americas' regional boundaries propels the narcolepsy market's growth. Europe is the second largest market for narcolepsy, followed by Asia Pacific, due to the availability of research funds, a huge patient population, a growing number of obese people, and the presence of industrialized economies such as France, Italy, and Germany within the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Narcolepsy market report based on type, treatment, diagnosis, end-user, and region.

Global Narcolepsy Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Narcolepsy market includes Jazz Pharmaceuticals plc., BIOPROJET, Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V.  Teva Pharmaceutical Industries Ltd., Novartis AG, Shire, Shionogi Inc.,  Ligand Pharmaceuticals, Inc., and Others. Jazz Pharmaceuticals plc is a major biopharmaceutical firm specialising in the development, production, and commercialization of sleep and hematology/oncology drugs. The company is working on finding innovative compounds for oncology and sleep treatments, as well as researching revolutionary drug solutions ranging from small molecule breakthroughs to biologics. Furthermore, the company is concentrating on acquiring new therapeutic product lines and forming collaborations in order to create promising early-stage medicines.

• Jazz Pharmaceuticals Plc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• BIOPROJET
• Arena Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Shire
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.
• Others

 “*” marked represents similar segmentation in other categories in the respective section